

## **2024 GOMRG Competition**

## **CCV attached**

Applicant: Dr. Florence T.H. Wu (fellow/co-PI)

**page 2 to 12**

Contact: Dr. Cheryl Ho (supervisor/PI)

**page 13 to 44**

### **Project Title**

Endothelial PD-L1 expression as a potential predictive biomarker in lung cancer treatment.

**Date Submitted:** 2024-09-29 23:03:47

**Confirmation Number:** 1834643

**Template:** Full CV

---

## **Dr. Florence Tien Hsin Wu**

Correspondence language: English

Sex: Female

Date of Birth: 6/26

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

Home (\*)

21 Burkebrook Place #419

Toronto Ontario M4G 0A2

Canada

### **Telephone**

Mobile (\*) 1-647-2872806

### **Email**

Personal (\*) florencethwu@gmail.com

Work florence.wu@phsa.ca

### **Website**

Personal <https://tinyurl.com/gsfTHW>

Personal <https://orcid.org/0000-0002-6439-4606>

## Dr. Florence Wu

---

### Language Skills

Language	Read	Write	Speak	Understand
Cantonese	Yes	Yes	Yes	Yes
English	Yes	Yes	Yes	Yes

### Degrees

2024/9 (2026/9)	Post-doctorate, Thoracic Medical Oncology, Clinical Fellowship, Princess Margaret Cancer Centre Degree Status: In Progress
2024/9 (2026/9)	Post-doctorate, Clinician Investigator Program, Post-Doctoral Research Fellowship, University of British Columbia Degree Status: In Progress
2022/9 - 2024/9	Post-doctorate, Medical Oncology, PGY4-5 Residency, University of British Columbia Degree Status: Completed
2019/7 - 2022/9	Post-doctorate, Internal Medicine, PGY1-3 Residency, University of British Columbia Degree Status: Completed
2009/9 - 2019/5	Doctorate, MD-PhD, PhD in Medical Biophysics, University of Toronto Degree Status: Completed Supervisors: Prof Robert S. Kerbel
2006/9 - 2009/5	Master's Thesis, Master of Science in Engineering, Biomedical Engineering, Johns Hopkins University Degree Status: Completed Supervisors: Prof Aleksander S. Popel
2002/9 - 2006/5	Bachelor's Honours, Bachelor of Applied Science, Honours, Engineering Science, University of Toronto Degree Status: Completed Supervisors: N/A

### Credentials

2024/6	FRCPC (Internal Medicine), Royal College of Physicians and Surgeons of Canada
--------	---

### Recognitions

2024/9 - 2025/9	** FRIEDMAN AWARD FOR SCHOLARS IN HEALTH (Canadian dollar) University of British Columbia Prize / Award
-----------------	---

2023/7 - 2024/6	LEE & LEQUELENEC YOUNG LEADERS AWARD (Canadian dollar) BC Cancer/UBC - Medical Oncology Residency Training Program Prize / Award
2016/9	Medical Biophysics Excellence Award (Canadian dollar) University of Toronto Prize / Award
2015/9	Doctoral Completion Award, Department of Medical Biophysics (Canadian dollar) University of Toronto Prize / Award
2014/9	James Lepock Memorial Award, Dept of Medical Biophysics (Canadian dollar) University of Toronto Prize / Award
2012/1	Keystone Symposium Scholarship (international conference travel award) (Canadian dollar) Keystone Symposia Prize / Award
2011/5 - 2014/4	** VANIER CANADA GRADUATE SCHOLARSHIP - 150,000 (Canadian dollar) Canadian Institutes of Health Research Prize / Award
2010/4	CREMS Program Summer Research Award (Canadian dollar) University of Toronto Prize / Award
2010/1 - 2019/4	MD/PhD Studentships, CIHR & McLaughlin Centre for Molecular Medicine (Canadian dollar) University of Toronto Prize / Award
2006/9 - 2008/8	** NSERC POST-GRADUATE SCHOLARSHIP - MASTER'S FOR TENURE ABROAD - 35,000 (Canadian dollar) Natural Sciences and Engineering Research Council of Canada (NSERC) Prize / Award
2006/9 - 2008/8	Dean's Fellowship, GWC Whiting School of Engineering (Canadian dollar) Johns Hopkins University Honor
2005/4	** NSERC UNDERGRADUATE STUDENT RESEARCH AWARD (Canadian dollar) IBBME, University of Toronto Prize / Award
2005/1	Murray F. Southcote Scholarship, Dept of Engineering Science (Canadian dollar) University of Toronto Prize / Award
2003/4	Golden Key Membership (Canadian dollar) G.K. International Honour Society Honor
2002/9 - 2006/4	Dean's Honours List, Dept of Engineering Science (Canadian dollar) University of Toronto Honor

Research Specialization Keywords: immune checkpoint inhibitors, anti-angiogenic therapies, tumour microenvironment, tumor immunology, tumor vascular biology

Disciplines Trained In: Oncology, Internal Medicine, Biology and Related Sciences, Biomedical Engineering and Biochemical Engineering

Research Disciplines: Oncology, Biology and Related Sciences, Biomedical Engineering and Biochemical Engineering

Areas of Research: Immunotherapy, Angiogenesis, Lung Cancer, Cancer of the Digestive System

Fields of Application: Biomedical Aspects of Human Health, Foundations and Knowledge Acquisition

## Employment

2024/9 - 2026/9	PGY6 Resident MD, Clinician Investigator Program PHSA & University of British Columbia
2024/9 - 2026/9	Clinical Fellow, Thoracic Medical Oncology Princess Margaret Cancer Centre
2022/9 - 2024/9	PGY4-5 Resident MD, Medical Oncology PHSA & University of British Columbia
2019/7 - 2022/9	PGY1-3 Resident MD, Internal Medicine PHSA & University of British Columbia
2004/5 - 2004/8	BASc Summer Student, Biomedical Engineering Toronto-Sunnybrook Regional Cancer Centre
2003/5 - 2003/8	BASc Summer Student, Structural Bioinformatics Blueprint.org / Hogue Laboratory, University of Toronto

## Affiliations

The primary affiliation is denoted by (\*)

2024/9 - 2026/9	Clinical Fellow, Thoracic Medical Oncology, Princess Margaret Cancer Centre
(*) 2024/9 - 2026/9	PGY6 Resident MD, Clinician Investigator Program, BC Cancer Vancouver, University of British Columbia

## Leaves of Absence and Impact on Research

2020/12 - 2021/3	Medical, PHSA & University of British Columbia 3 months off-cycle in clinical training
------------------	---

## Research Funding History

### Awarded [n=1]

2013/9 - 2015/8 Co-applicant	2013 Operating Grant, Cancer Research Society, Grant, Operating Clinical Research Project?: No Project Description: <b>First-authored Operating Grant proposal</b> , "Inhibition of metastatic spread with an Angiopoietin-1 mimetic drug" Written for Prof. Daniel J. Dumont (PI) & Prof. Robert S. Kerbel (co-PI). <u>Funded</u> by the <i>Cancer Research Society (CRS)</i> in 2013 (\$58,200/yr x 2 years).
---------------------------------	---

## Editorial Activities

2016/9 - 2017/8	Associate Editor, University of Toronto Medical Journal, Journal
2012/9 - 2013/8	Senior Editor, Health Science Inquiry, Journal
2011/9 - 2012/8	Reviewer/Junior Editor, Health Science Inquiry, Journal
2012/1 - 2012/5	Chapter Editor, Clinical Pharmacology, Toronto Notes 2013, Book
2010/9 - 2011/8	Section Editor, University of Toronto Medical Journal, Journal

## Mentoring Activities

2023/7 - 2024/1	Residents as Teachers Certificate Program, University of British Columbia
2021/7 - 2021/7	PGY3 Instructor, Bootcamp for PGY1s, University of British Columbia Number of Mentorees: 18 lumbar punctures, thoracentesis, paracentesis sessions
2007/9 - 2008/8	Teaching Assistant, Johns Hopkins University Number of Mentorees: 90 580.422 Systems Bioengineering II: Neural Systems / 580.423 Systems Bioengineering I: Cells & Cardiovascular System / 580.223 Models and Simulations

## Conference Review Activities

2024/1 - 2024/1	Essay Competition Adjudicator, ONCARE (Oncology National Course for Advocacy, Research, and Education); virtual course for medical students led by Dr. Paris-Ann Ingledew), Blind Number of Works Reviewed / Refereed: 4
2012/12 - 2013/1	Abstract Judge, Oral Presentation Selection Committee, Medical Student Research Day, Blind, University of Toronto Number of Works Reviewed / Refereed: 5

## Community and Volunteer Activities

2023/11 - 2023/11	Volunteer, Lung Cancer Patient Summit (Vancouver)
-------------------	---

## Other Memberships

Trainee Membership, SITC, Society for Immunotherapy of Cancer (2024-)

Trainee Membership, ESMO, European Society for Medical Oncology (2022-)

Trainee Membership, IASLC, International Association for the Study of Lung Cancer (2023-)

Trainee Membership, CITAC, Clinician Investigator Trainee Association of Canada (2009-)

Trainee Membership, CCTG, Canadian Cancer Trials Group (Medidata/Rave EDC account, 2021)

Trainee Membership, AACR, American Association for Cancer Research (2024-)

Trainee Membership, ASCO, American Society of Clinical Oncology (2018-)

Trainee Membership, BMES, Biomedical Engineering Society (2008-09)

Trainee Membership, ASTRO, American Society of Clinical Oncology (2024)

## Presentations

1. (2024). "ASCO Update". 2024 Canadian Association of General Practitioners in Oncology Meeting, Vancouver, Canada  
Main Audience: Knowledge User  
Invited?: Yes
2. (2024). Breakout Session for Nursing: "Genomics in the Context of Lung Cancer Treatment". 2024 Canadian Lung Cancer Conference, Vancouver, Canada  
Main Audience: Knowledge User  
Invited?: Yes
3. (2023). "Managing systemic therapy side effects in lung cancer.". 2023 Breathing Better Week (Virtual Symposium), Lung Health Foundation, Vancouver, Canada  
Main Audience: Knowledge User  
Invited?: Yes
4. (2015). "Can we use an Angiopoietin-1 mimetic to inhibit metastatic spread?". Scientific Exchange | Regeneron Pharmaceuticals, Inc., Tarrytown, New York, New York, United States of America  
Main Audience: Researcher  
Invited?: Yes

## Publications

### Journal Articles

1. Wu FTH, Rittberg R, Lim K, and Ho C. (2024). Treating anaplastic lymphoma-kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy. *BMJ Case Reports*. 2024 Mar 25; 17(3):e255575 [CASE REPORT].  
First Listed Author  
Published,  
Refereed?: Yes
2. D'Amours M, Wu FTH, Thiesen-Lauk O, Chan E, McGuire A, Ho C. (2024). Surgically resectable non-small cell lung cancer: a contemporary approach. *European Respiratory Journal*. 2024 Aug 8;64(2):2400332 [REVIEW].  
Co-Author  
Published,  
Refereed?: Yes
3. Wu FTH, Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Drusbosky L, Renouf DJ, Jonker DJ, Tu D, Chen EX, and Loree JM. (2024). Kinetic profiling of *RAS* mutations with circulating tumor DNA in the CCTG CO.26 trial suggests the loss of *RAS* mutations in neo-*RAS*-wildtype metastatic colorectal cancer is transient.. *JCO Precision Oncology*. 2024 Aug;8:e2400031.  
First Listed Author  
Published,  
Refereed?: Yes

4. Wu FTH, Ho C. (2023). Primer on systemic therapies for advanced lung cancers in 2023. *Journal of Family Practice Oncology*, www.fpon.ca, Issue # 41 (Fall 2023), p.25-27. [REVIEW].  
First Listed Author  
Published,  
Refereed?: No
5. Wu FTH, Diab M, Myers R, Ho C, Lam S, McGuire A. (2023). Update on Lung Cancer. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*. 2023 Jul 17; 7:4, 201-205 [REVIEW].  
First Listed Author  
Published,  
Refereed?: Yes
6. Khan KA\*, Wu FTH\*, Cruz-Muñoz W and Kerbel RS. (\*co-first authors). (2021). Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. *EMBO Molecular Medicine*. 2021 Jul 7;13(7): e08253. [REVIEW].  
First Listed Author  
Published,  
Refereed?: Yes
7. Wu FTH, Xu P, Chow A, Man S, Krueger J, Khan KA, Paez-Ribes M, Pham E and Kerbel RS. (2019). Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. *British Journal of Cancer*. 120(2): 196-206.  
First Listed Author  
Published,  
Refereed?: Yes
8. Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FTH, Miller V, Andrews D and Kerbel RS. (2016). Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. *Cancer Research*. 2016 Oct 15;76(20):5983-5993.  
Co-Author  
Published,  
Refereed?: Yes
9. Wu FTH, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. (2016). Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. *Scientific Reports*. 2016 Nov 14;6:36694.  
First Listed Author  
Published,  
Refereed?: Yes
10. Wu FTH, Man S, Xu P, Paez-Ribes M, Lee CR, Pirie-Shepherd SR, Emmenegger U and Kerbel RS. (2016). Efficacy of co-targeting Angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal and renal cancers. *Cancer Research*. 2016 Dec 1;76(23):6988-7000.  
First Listed Author  
Published,  
Refereed?: Yes
11. Wu FTH, Lee CR, Bogdanovic E, Prodeus A, Garipey J and Kerbel RS. (2015). Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. *EMBO Molecular Medicine*. 2015 April 7;7(6):770-87.  
First Listed Author  
Published,  
Refereed?: Yes



12. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. (2010). Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. *Cancer Research*. 2010 Dec 1; 70(23):9886-9894.  
Co-Author  
Published,  
Refereed?: Yes
13. Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. (2010). A systems biology perspective on sVEGFR1: its biological function, pathogenic role & therapeutic use. *Journal of Cellular and Molecular Medicine*. 2010 Mar; 14(3):528-552. [REVIEW].  
First Listed Author  
Published,  
Refereed?: Yes
14. Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. (2010). VEGF and soluble VEGF receptor-1 distribution in peripheral arterial disease: an in silico model. *American Journal of Physiology – Heart and Circulatory Physiology*. 2010 Jun; 298(6):H2174-91.  
First Listed Author  
Published,  
Refereed?: Yes
15. Wu FTH, Stefanini MO, Mac Gabhann F, Popel AS. (2009). Chapter 18: Modeling of growth factor-receptor systems: from molecular-level protein interaction networks to whole-body compartment models. *Methods in Enzymology*. 2009; 467:461-497. [BOOK CHAPTER].  
First Listed Author  
Published,  
Refereed?: Yes
16. Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. (2009). Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: Effects of transendothelial and lymphatic macromolecular transport. *Physiological Genomics*. 2009 Jun 10; 38(1):29-41.  
First Listed Author  
Published,  
Refereed?: Yes
17. Wu FTH, Stefanini MO, Mac Gabhann F, Popel AS. (2009). A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. . *PLoS ONE*. 2009; 4(4): e5108.  
First Listed Author  
Published,  
Refereed?: Yes
18. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. (2009). The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. *PLoS Computational Biology*. 2009 Dec; 5(12):e1000622.  
Co-Author  
Published,  
Refereed?: Yes
19. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. (2008). A compartmental model of VEGF distribution in blood, healthy and diseased tissues. *BMC Systems Biology*. 2008 Aug 19; 2(1):77.  
Co-Author  
Published,  
Refereed?: Yes

20. Whyne C, Hardisty M, Wu F, Skrinkas T, Clemons M, Gordon L, Basran PS. (2007). Quantitative characterization of metastatic disease in the spine. Part II. Histogram-based analyses. *Medical Physics*.  
Co-Author  
Published,  
Refereed?: Yes
21. Wu FTH, Ng-Thow-Hing V, Singh K, Agur AM, McKee NH. (2007). Computational representation of the aponeuroses as NURBS surfaces in 3D musculoskeletal models. *Computer Methods and Programs in Biomedicine*. 2007 Nov; 88(2):112-22.  
First Listed Author  
Published,  
Refereed?: Yes

## Conference Publications

1. Wu FTH, D'Amours M-F, Usman F, Hussein A, Bhang E, Kamali Sarvestani M, Lee CW, Ho C. (2024). Real-world prognostic & predictive implications of EORTC & MRS scores for immunotherapy and chemotherapy in pleural mesothelioma. [Abstract#P4.14C-03; Poster Tour Presentation #PT02.14]. 2024 World Conference on Lung Cancer, San Diego, United States of America,  
Conference Date: 2024/9  
Poster  
First Listed Author  
Refereed?: Yes  
Number of Contributors: 8
2. Wu FTH, Yip S, Usman F, Sabag S, Hughesman C, Ng T, Alex D, Khoo KE, Bosma N, Laskin J, Lim H, Chia SK, Ko-Leong J, Pollard S, Weymann D, Demarco P, Regier DA, Chau N, Ho C. (2024). Comprehensive genomic characterization of thyroid cancers: real-world implementation and impact on clinical decisions. [Abstract #227]. 2024 Multidisciplinary Head and Neck Cancers Symposium, Phoenix, United States of America,  
Conference Date: 2024/3  
Poster  
First Listed Author  
Refereed?: Yes  
Number of Contributors: 19
3. Wu FTH, Bhang E, Kamali Sarvestani M, Lee CW, Ho C. (2023). Impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma: a real-world analysis. [Abstract #P2.18-05]. 2023 World Conference on Lung Cancer, singapore, Singapore,  
Conference Date: 2023/9  
Poster  
First Listed Author  
Refereed?: Yes  
Number of Contributors: 5
4. Wu FTH, Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Banks KC, Renouf DJ, Jonker DJ, Tu D, Chen EX, and Loree JM . (2023). Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial. [Abstract #3567]. 2023 ASCO Annual Meeting, Chicago, United States of America,  
Conference Date: 2023/6  
Poster  
First Listed Author  
Refereed?: Yes  
Number of Contributors: 11

5. Ho C, Wu F, Humphreys M, Johal B, Laskin J, Rao S, Taylor S, Wang Y, Lee C. (2023). Ipilimumab plus Nivolumab for advanced malignant pleural mesothelioma: implementation into clinical practice. [Abstract PO-016]. 16th iMig conference, Lille, France,  
Conference Date: 2023/6  
Poster  
Co-Author  
Refereed?: Yes  
Number of Contributors: 9
6. Wu FTH, Lee CR, Man S, Pirie-Shepherd S, Koh GY and Kerbel RS. (2014). Differential effects of VEGFR2-targeting TKIs and Tie2 pathway-targeting (anti-Ang2 or pro-Ang1) agents on breast cancer metastasis to the lung. [Poster presentation #14]. 16th International Symposium on Anti-Angiogenic Therapy, San Diego, United States of America,  
Conference Date: 2014/2  
Poster  
First Listed Author  
Refereed?: Yes
7. Wu FTH, Lee CR, Van Slyke P, Dumont DJ and Kerbel RS. (2012). Manipulating the Angiopoietin-Tie2 pathway to reduce metastases. Keystone Symposia - Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States of America,  
Conference Date: 2012/1  
Poster  
First Listed Author  
Refereed?: Yes
8. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. (2009). Effects of an anti-VEGF administration on whole-body VEGF distribution assessed by a molecularly-detailed pharmacokinetic model: a cancer study. Experimental Biology 2009, New Orleans, United States of America,  
Conference Date: 2009/4  
Poster  
Co-Author  
Refereed?: Yes
9. Wu FTH, Stefanini MO, Mac Gabhann F, Popel AS. (2008). Anti-angiogenic potential of sVEGFR1 for trapping VEGF assessed by a multi-compartmental model.[Podium Presentation #354]. Biomedical Engineering Society Annual Fall Meeting; Oct 2-4, 2008; St. Louis, MO, USA., St. Louis, United States of America,  
Conference Date: 2008/10  
Abstract  
Refereed?: Yes
10. Wu F, Burnes D, Gordon L, Hardisty M, Skriskas T, Basran P, Whyne CM. (2006). Quantitative Characterization of Metastatic Progression in the Spine through Automated CT Analysis. [Podium Presentation #21] [J Bone Joint Surg Br Proceedings Vol 90-B: Supplement: 129]. 61st Canadian Orthopaedic Association /40th Canadian Orthopaedic Research Society Annual Meeting; June 2-4, 2006; Toronto, ON, Canada., Toronto, Canada,  
Conference Date: 2006/6  
Abstract
11. Wu F, Burnes D, Gordon L, Hardisty M, Skriskas T, Basran P, Whyne CM. (2006). Quantitative Characterization of Metastatic Progression in the Spine and Development of an Automated Tracking Tool.[abstract: Transactions Vol.31, Paper No.1854]. 52nd Annual Meeting of the Orthopaedic Research Society, Chicago, United States of America,  
Conference Date: 2006/3  
Poster  
Refereed?: Yes

12. Gordon L, Hardisty M, Skrinkas T, Wu F, Whyne CM. (2006). Atlas-Based Segmentation in the Metastatic Spine via 3D Deformable Registration [abstract: Transactions Vol.31, Paper No.0731]. 52nd Annual Meeting of the Orthopaedic Research Society, Chicago, United States of America, Conference Date: 2006/3  
Poster  
Co-Author

## Intellectual Property

### Disclosures

1. Therapeutic potential of PEGylated compound(s) for vascular dependent conditions or diseases. Co-inventors: Florence Wu, Robert Kerbel, Jean Gariepy. <Sunnybrook Research Institute #SB395> <MaRS Innovation #MI2014-217>  
Protected  
Date Issued: 2014/12  
Filing Date: 2014/12/10

**Date Submitted:** 2024-09-19 22:53:13

**Confirmation Number:** 1827891

**Template:** Full CV

---

## **Dr. Cheryl Ho**

Correspondence language: English

Sex: Female

Date of Birth: 11/16

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

Primary Affiliation (\*)

BC Cancer  
600 W 10th Avenue  
Vancouver British Columbia V5Z 4E6  
Canada

### **Telephone**

Fax	604-877 0585
Work (*)	604-877 6000 extension: 2445

### **Email**

Work (*)	cho@bccancer.bc.ca
----------	--------------------

### **Website**

Corporate	<a href="https://medicaloncology.med.ubc.ca/dr-cheryl-ho/">https://medicaloncology.med.ubc.ca/dr-cheryl-ho/</a>
-----------	---

## Dr. Cheryl Ho

---

### Language Skills

Language	Read	Write	Speak	Understand
English	Yes	Yes	Yes	Yes
French	No	No	No	No

### Degrees

2017/9 - 2018/4	Certificate, Health Economics for Health Professionals, University of Aberdeen Degree Status: Completed
2005/7 - 2006/7	Post-doctorate, Thoracic oncology fellowship - Fellow, Medical Oncology, University of California, Davis Degree Status: Completed
2003/7 - 2005/6	Post-doctorate, Medical Oncology - Fellow, Medical Oncology, BC Cancer Agency Degree Status: Completed Supervisors: Dr. Tamara Shenkier
2000/7 - 2003/6	Post-doctorate, Internal Medicine - Fellow, Internal Medicine, University of Western Ontario Degree Status: Completed Supervisors: Dr. Karen Fruetel
1996/9 - 2000/5	Doctorate Equivalent, Medical degree - M.D., University of Western Ontario Degree Status: Completed Supervisors: Dean, Dr. C. Herbert
1994/9 - 1996/9	Master's Thesis, Master's of Science - Masters, Biochemistry, University of Toronto Degree Status: Completed Supervisors: Dr. D.M. Clarke
1990/9 - 1994/5	Bachelor's, Bachelor's of Science, Biochemistry, University of Toronto Degree Status: Completed Supervisors: Dean, Dr. Chandler

### Recognitions

2017/7 - 2018/6	Honor Roll for Clinical Teaching Excellence University of British Columbia
2016/7 - 2017/6	Resident mentorship award BC Cancer Agency

2005/5	Novartis Oncology Young Canadian Investigators Award Novartis Prize / Award
2005/3	CAMO Travel Fellowship award Canadian Association of Medical Oncology Prize / Award
2004/6	Amgen Canada Fellows Alliance ASCO award Amgen Prize / Award
2002/5	UWO Department of Medicine Faculty-Resident Research day - Best oral presentation University of Western Ontario Distinction
2000/5	Collins Memorial Prize in Geriatric Medicine - 0 University of Western Ontario Distinction
2000/5	Canada Millenium Scholarship - 0 Government of Canada Prize / Award
1998/7	Ivan H. Smith Oncology studentship - 0 Cancer Care Ontario and Canadian Cancer Society Prize / Award
1996/8 - 1997/8	Dean's Honor List, 1st year medicine - 0 University of Western Ontario Distinction
1996/6	Silver Medal in Biochemistry - 0 St. Michael's College, University of Toronto Distinction
1994/9 - 1996/9	Ontario Graduate Scholarship Provincial government of Ontario Prize / Award
1994/9 - 1996/9	Norman Stuart Robertson Graduate Studies fellowship University of Toronto Prize / Award
1991/6	John D. Schultz Science Student scholarship Heart and Stroke Foundation of Canada Prize / Award
1990/9 - 1994/9	Canada Scholarship - 0 Government of Canada Prize / Award
1990/9 - 1994/9	St. Michael's College Foundation Scholarship - 0 University of Toronto Prize / Award
1990/9 - 1994/9	Faculty of Arts and Science Scholar - 0 University of Toronto Distinction

Engaged in Clinical Research?: Yes

Research Specialization Keywords: Head and neck cancer, Lung cancer, Nasopharyngeal carcinoma

Disciplines Trained In: Oncology

Research Disciplines: Oncology

Areas of Research: Head and Neck Cancer, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

## Employment

2014/8	Clinical Associate Professor Medicine, Division of Medical Oncology, University of British Columbia
2006/9	Medical Oncologist Medical Oncology, BC Cancer Agency, UBC, BC Cancer Agency Full-time
2006/9	Medical Oncologist BC Cancer Agency
2007/7 - 2014/8	Clinical Assistant Professor Medicine, Medicine, University of British Columbia Full-time, Assistant Professor Tenure Status: Non Tenure Track

## Affiliations

The primary affiliation is denoted by (\*)

2014/7	Clinical associate professor, University of British Columbia
(*) 2006/9	Medical oncologist, BC Cancer Agency

## Courses Taught

2011/09/06	Clinical preceptor, University of British Columbia Course Title: Ambulatory clinics in clinical clerkship Course Code: MEDI430
2007/09/04	Lecturer, BC Cancer Agency Course Title: Graduate students course in oncology Course Code: ONC502
2007/09/04	Clinical preceptor, BC Cancer Agency Course Title: Ambulatory clinic preceptor for medical student and resident electives
2006/07/04	Lecturer, University of British Columbia Course Title: Academic half day UBC medical oncology
2006/07/04	Lecturer, BC Cancer Agency Course Title: General practitioner in oncology course

## Program Development

Post graduate medical oncology fellowship director, BC Cancer Agency



## Student/Postdoctoral Supervision

### Doctorate Equivalent [n=2]

2015/6 - 2016/6 Principal Supervisor	Jennifer Siegfried (In Progress) , University of British Columbia Student Degree Start Date: 2015/8 Thesis/Project Title: Surveillance of resected NSCLC Present Position: Medical school
2014/6 - 2015/6 Principal Supervisor	Andrew Yamata (In Progress) , UBC Student Degree Start Date: 2014/1 Thesis/Project Title: Early versus late brain metastasis in NSCLC Project Description: Early versus late brain metastasis in NSCLC Present Position: Residency

### Post-doctorate [n=12]

2023/11 - 2025/4 Principal Supervisor	Marie Frederique D'amours (In Progress) , BC Cancer Student Degree Start Date: 2023/11 Student Degree Expected Date: 2025/4 Thesis/Project Title: Patterns of stage III NSCLC management and recurrence Present Position: Medical oncology fellow
2022/9 - 2026/9 Principal Supervisor	Florence Wu (In Progress) , BC Cancer Student Degree Start Date: 2022/9 Student Degree Expected Date: 2026/9 Thesis/Project Title: Management of mesothelioma in the era of immunotherapy Endothelial PDL1 as a biomarker for immunotherapy Present Position: Medical oncology fellow
2021/9 - 2022/8 Principal Supervisor	Rebekah Rittberg (Completed) , BC Cancer Student Degree Start Date: 2021/9 Student Degree Received Date: 2022/8 Thesis/Project Title: Checkpoint inhibition in advanced wild type NSCLC Present Position: Medical oncologist
2018/9 - 2019/5 Principal Supervisor	Alexandra Pender, BC Cancer Thesis/Project Title: ctDNA testing in EGFR mutation positive NSCLC Present Position: Medical oncologist
2018/7 - 2019/6 Principal Supervisor	Zamzam Al-hashami, BC Cancer Thesis/Project Title: Chemotherapy use in NSCLC Present Position: Medical oncologist
2018/7 - 2019/6 Co-Supervisor	Alannah Smrke, BC Cancer Thesis/Project Title: Patient reported outcomes in AYA vs older populations with cancer Present Position: Medical oncologist
2018/7 - 2019/6 Principal Supervisor	Maryam Soleimani, BC Cancer Thesis/Project Title: Patient reported outcomes in testes cancer Present Position: Medical oncologist

2018/7 - 2020/6 Principal Supervisor	Selina Wong (Completed) , BC Cancer Student Degree Start Date: 2018/7 Student Degree Received Date: 2020/6 Student Canadian Residency Status: Canadian Citizen Thesis/Project Title: Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage. Present Position: Medical oncologist
2017/7 - 2019/6 Principal Supervisor	Sara Moore (In Progress) , BC Cancer Student Degree Start Date: 2013/7 Student Degree Expected Date: 2017/7 Student Canadian Residency Status: Canadian Citizen Thesis/Project Title: Recurrent versus de novo metastatic NSCLC: Outcomes Present Position: Post graduate fellow
2016/7 - 2017/6 Principal Supervisor	Negar Chooback, BC Cancer Thesis/Project Title: CNS metastases in EGFR mutation positive NSCLC Present Position: Medical oncologist
2014/7 - 2016/7 Co-Supervisor	Ben Maas (In Progress) , UBC Student Degree Start Date: 2014/1 Thesis/Project Title: Neoadjuvant chemotherapy in NPC – the impact on treatment delivery Project Description: Neoadjuvant chemotherapy in NPC – the impact on treatment delivery Present Position: Radiation oncologist
2014/7 - 2016/6 Co-Supervisor	Brandon Sheffield (In Progress) , UBC Student Degree Start Date: 2014/1 Thesis/Project Title: Primary and nodal tissue microarray of resected NSCLC: Prognostic and predictive factors Project Description: Primary and nodal tissue microarray of resected NSCLC: Prognostic and predictive factors Present Position: Pathologist

## Event Administration

2007/7	Co-chair, BC Cancer Agency Canadian Lung Cancer Conference, Conference Co-chair a Western Canadian meeting with a multi-disciplinary focus to meet the needs of a wide variety of professionals. The curriculum addresses the needs of Medical Oncology, Respiratory Medicine, Radiation Oncology and Thoracic Surgery as well as Oncology Nursing with a special interest in lung oncology.
2010/7 - 2021/7	Co-chair, BC Cancer Agency Provincial Head and Neck Retreat, Seminar Co-chair a national meeting with a multi-disciplinary focus to meet the needs of a wide variety of professionals. The curriculum addresses the needs of Medical Oncology, Respiratory Medicine, Radiation Oncology and Thoracic Surgery as well as Oncology Nursing with a special interest in lung oncology.

## Editorial Activities

2016/7	Editorial board, Cochrane Lung Cancer Review Group, Journal
2016/2	Web Editor, Journal of Thoracic Oncology, Journal Member of the editorial board
2020/1 - 2022/1	Editorial board, Journal of Thoracic Oncology: Clinical and Research Reports, Journal

## Journal Review Activities

Reviewer, Onco Targets and Therapy  
 Reviewer, European Journal of Cancer  
 Reviewer, Annals of Respiratory Medicine  
 Reviewer, Lung Cancer  
 Reviewer, Clinical Lung Cancer  
 Reviewer, Cancer

## Research Funding Application Assessment Activities

External Reviewer, Precision Health Catalyst Grants, Organization, Academic Reviewer, University of British Columbia  
 External Reviewer, Canadian Cancer Society Data Transformation Grants, Organization, Academic Reviewer, Canadian Cancer Society Research Institute  
 External Reviewer, Cancer Care Manitoba

## Event Participation

2005/6 - 2005/6 , FECS AACR ASCO Methods in Clinical Cancer Research workshop, Workshop

## Committee Memberships

2018/11	Committee Member, Radioactive iodine refractory thyroid cancer consensus guideline working group member
2018/4	Committee Member, Cancer Care Ontario's Guideline Development Working Group member - Chemotherapy with Radiotherapy for Nasopharyngeal Cancer
2017/1	Chair, Medical Director – BCCA Compassionate Access Program, BC Cancer Agency
2016/7	Committee Member, Pan-Canadian Oncology Drug Review – Clinical Guidance Committee
2016/1	Committee Member, Board of Directors – Lung Cancer Canada
2012/3	Chair, Post-graduate medical oncology fellowship director, BC Cancer Agency
2008/9	Committee Member, Accreditation committee - medication management, BC Cancer Agency
2008/9	Chair, Provincial systemic leader head and neck tumor group, BC Cancer Agency
2008/1	Committee Member, Oncology outcomes and surveillance integrated system, BC Cancer Agency

## Other Memberships

2006/4	Member, International Association for the Study of Lung Cancer
2003/7	Member, American Society of Clinical Oncology

2003/7

Member, Canadian Association of Medical Oncologist

## Most Significant Contributions

2021/3

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

Examination of the duration of adjuvant treatment for the most common types of cancers was used as evidence to support and change the duration of Canadian employment insurance benefits. <https://cancer.ca/en/about-us/media-releases/2022/ei-sickness-benefit-implementation>

Open Label, Multicenter, Phase II Study of Patients with Treatment Naïve Metastatic EGFR Mutation-Positive NSCLC with Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone.

Co-principal investigator of investigator initiated clinical trial Value: 1.3 M over 5 years  
Impact: The goal of this prospective randomized trial is to evaluate the efficacy of treating minimally symptomatic brain metastases with a TKI alone compared to radiotherapy approaches. Given the higher CNS penetration of osimertinib compared to other TKIs and promising intracranial control rates demonstrated in recent clinical trials, we aim to establish the value of osimertinib alone versus with stereotactic radiosurgery.

PREDiCT: PReCision oncology Evidence Development in Cancer Treatment.

Co-principal investigator: PREDiCT PReCision oncology Evidence Development in Cancer Treatment. Value \$8M over 3 years. Impact: Goal is to develop a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers regarding drug reimbursement

Research in patient reported outcomes and marginalized populations

Examination of psychosocial distress in adolescents and young adults has led to the launch of new BC Cancer resources <http://www.bccancer.bc.ca/health-info/adolescent-young-adult> 1. . Distinct features of psychosocial distress of adolescents and young adults with cancer compared to adults at diagnosis: Patient-reported domains of concern. J Adolesc Young Adult Oncol. 2020 Apr 7. doi: 10.1089/jayao.2019.0157. Studies in the care of low English proficiency patients provide insight into building appropriate resources 1. Patient-reported outcomes in a linguistically diverse cancer population: Addressing barriers to access. Abstract 387134 ASCO Quality Care Symposium Sept 2022 2. End-of-life health resource utilization for limited English proficient patients with advanced non-small

## Presentations

1. (2023). Lung Cancer - Current Management and Understanding Prognosis in our Patients. UBC Practical Cancer Care for Primary Point of Care Providers, Vancouver, Canada  
Invited?: Yes
2. (2023). Exploring the Non-Surgical Management of Mesothelioma. Canadian Surgical Forum, Vancouver, Canada  
Invited?: Yes
3. (2023). The Case for Combination Chemo-Immunotherapy over Sequential Treatment in Advanced NSCLC. World Conference on Lung Cancer, Singapore, Singapore  
Invited?: Yes

4. (2022). EGFR positive lung cancer with CNS disease Is less more? Osimertinib alone or with SRS. Sunnybrook Hospital Noon Rounds, Toronto, Canada  
Invited?: Yes
5. (2021). PREDiCT: Implementing a precision oncology learning healthcare system at BC Cancer. BC Cancer Summit, Vancouver, Canada  
Invited?: Yes
6. (2021). Real World Evidence. Concertation table on precision medicine, Montreal, Canada  
Invited?: Yes
7. (2021). PREDiCT: Implementing a precision oncology learning healthcare system at BC Cancer. PReCISION oncology Evidence Development in Cancer Treatment. Conference on Hematology and Oncology, Whistler, Canada  
Invited?: Yes

## Publications

### Journal Articles

1. Nunez JJ , Leung B , Ho C , Ng RT , Bates AT. (2024). Predicting which patients with cancer will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing. *Communications medicine*. 4(1): 69.  
Published,
2. Pollard S , Ehman M , Hermansen A , Weymann D , Krebs E , Ho C , Lim HJ , Jones S , Bombard Y , Hanna TP , Hessels C , Longstaff H , Cook-Deegan R , Bubela T , Regier DA. (2024). "I Just Assumed This Was Already Being Done": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology. *JCO precision oncology*. 8: e2400184.  
Published,
3. Wu F , Rittberg R , Lim K , Ho C. (2024). Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy. *BMJ case reports*. 17(3)  
Published,
4. Robledo KP , Lefresne S , Soon YY , Sahgal A , Pinkham MB , Nichol A , Soo RA , Parmar A , Hegi-Johnson F , Doherty M , Solomon BJ , Shultz DB , Tham IW , Sacher AG , Tey J , Leong CN , Koh WY , Huang Y , Ang YLE , Low J , Yong C , Lim MC , Tan AP , Lee CK , Ho C. (2024). Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. *BMJ open*. 14(7): e078335.  
Published,
5. Kalloger SE , Ho C , Mitton C , Regier DA. (2024). Mapping the experiences of people with advanced cancer across multiple cancer types-a scoping review. *Journal of cancer survivorship : research and practice*. 18(2): 318-324.  
Published,
6. Connor Wells J , Mullin MM , Ho C , Melosky B , Laskin J , Wang Y , Sun S. (2024). Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial. *Lung cancer (Amsterdam, Netherlands)*. 190: 107529.  
Published,
7. D'Amours MF , Wu FTH , Theisen-Lauk O , Chan EK , McGuire A , Ho C. (2024). Surgically resectable nonsmall cell lung cancer: a contemporary approach. *The European respiratory journal*. 64(2)  
Published,

8. Denault MH , Ho C. (2023). The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management. *Translational cancer research*. 12(3): 680-683.  
Published,
9. Anagnostou V , Ho C , Nicholas G , Juergens RA , Sacher A , Fung AS , Wheatley-Price P , Laurie SA , Levy B , Brahmer JR , Balan A , Niknafs N , Avrutin E , Zhu L , Sausen M , Bradbury PA , O'Donnell-Tormey J , Gaudreau PO , Ding K , Dancey J. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. *Nature medicine*. 29(10): 2559-2569.  
Published,
10. Silver A , Ho C , Ye Q , Zhang J , Janzen I , Li J , Martin M , Wu L , Wang Y , Lam S , MacAulay C , Melosky B , Yuan R. (2023). Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. *Current oncology (Toronto, Ont.)*. 30(6): 5546-5559.  
Published,
11. Leung B , Shokoohi A , Al-Hashami Z , Moore S , Pender A , Wong SK , Wang Y , Wu J , Ho C. (2023). Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults. *BMC cancer*. 23(1): 360.  
Published,
12. Mathers B , Abadi S , Davies JM , McIntyre C , Ho C. (2023). Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 29(6): 1381-1386.  
Published,
13. Rittberg R , Leung B , Shokoohi A , Pender A , Wong S , Al-Hashami Z , Wang Y , Ho C. (2023). Real-World Outcomes of Stage IV NSCLC with PD-L1  $\geq$  50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. *Current oncology (Toronto, Ont.)*. 30(6): 5299-5308.  
Published,
14. Nunez JJ , Leung B , Ho C , Bates AT , Ng RT. (2023). Predicting the Survival of Patients With Cancer From Their Initial Oncology Consultation Document Using Natural Language Processing. *JAMA network open*. 6(2): e230813.  
Published,
15. Rahmim A , Toosi A , Salmanpour MR , Dubljevic N , Janzen I , Shiri I , Yuan R , Ho C , Zaidi H , MacAulay C , Uribe C , Yousefirizi F. (2023). Tensor radiomics: paradigm for systematic incorporation of multi-flavoured radiomics features. *Quantitative imaging in medicine and surgery*. 13(12): 7680-7694.  
Published,
16. Li K , Bosdet I , Yip S , Ho C , Laskin J , Melosky B , Wang Y , Sun S. (2023). Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer. *Current oncology (Toronto, Ont.)*. 30(8): 7099-7111.  
Published,
17. Denault MH , Feng J , Kuang S , Shokoohi A , Leung B , Liu M , Berthelet E , Laskin J , Sun S , Zhang T , Ho C , Melosky B. (2023). Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. *Current oncology (Toronto, Ont.)*. 30(8): 7499-7507.  
Published,
18. Cressman S , Weber MF , Ngo PJ , Wade S , Behar Harpaz S , Caruana M , Tremblay A , Manser R , Stone E , Atkar-Khattra S , Karikios D , Ho C , Fernandes A , Yi Weng J , McWilliams A , Myers R , Mayo J , Yee J , Yuan R , Marshall HM , Fong KM , Lam S , Canfell K , Tammemägi MC. (2023). Economic impact of using risk models for eligibility selection to the International lung screening Trial. *Lung cancer (Amsterdam, Netherlands)*. 176: 38-45.  
Published,

19. Rittberg R , Abraham N , Laskin J , Ho C. (2022). Hyper-Sensitive? Targeted Therapy With a Primed Immune System. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 17(6): 734-736.  
Published,
20. Rittberg R , Ho C , Wang Y. (2022). Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis. *Cureus*. 14(4): e24513.  
Published,
21. Rittberg R , Chan E , Yip S , Alex D , Ho C. (2022). Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab. *Cureus*. 14(2): e22159.  
Published,
22. Jones L , Rittberg R , Leung B , Shokoohi A , Pender A , Wong S , Al-Hashami Z , Wang Y , Ho C. (2022). Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS  $\geq$  50%: 3 Weekly Compared to 6 Weekly Dosing. *Current oncology (Toronto, Ont.)*. 29(11): 8686-8692.  
Published,
23. Rittberg R , Leung B , Al-Hashami Z , Ho C. (2022). Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. *Frontiers in oncology*. 12: 1002385.  
Published,
24. Ho C , Lim HJ , Regier DA. (2022). FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment. *Current oncology (Toronto, Ont.)*. 29(2): 402-410.  
Published,
25. Leung B , Wong SK , Ho C. (2022). End-of-Life Health Resource Utilization for Limited English-Proficient Patients With Advanced Non-Small-Cell Lung Cancer. *JCO oncology practice*. 18(10): e1716-e1724.  
Published,
26. Shokoohi A , Al-Hashami Z , Moore S , Pender A , Wong SK , Wang Y , Leung B , Wu J , Ho C. (2022). Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world. *Cancer medicine*. 11(1): 86-93.  
Published,
27. Hilzenrat RA , Yip S , Melosky B , Ho C , Laskin J , Sun S , Choi JJ , McGuire AL. (2022). Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. *Current oncology (Toronto, Ont.)*. 30(1): 145-156.  
Published,
28. Denault MH , Kuang S , Shokoohi A , Leung B , Liu M , Berthelet E , Laskin J , Sun S , Zhang T , Melosky B , Ho C. (2022). Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report. *JTO clinical and research reports*. 3(5): 100316.  
Published,
29. Rittberg R , Leung B , Al-Hashami Z , Ho C. (2022). Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. *Current oncology (Toronto, Ont.)*. 29(12): 9744-9752.  
Published,
30. Pollard S , Weymann D , Chan B , Ehman M , Wordsworth S , Buchanan J , Hanna TP , Ho C , Lim HJ , Lorgelly PK , Raymakers AJN , McCabe C , Regier DA. (2022). Defining a Core Data Set for the Economic Evaluation of Precision Oncology. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 25(8): 1371-1380.  
Published,

31. Regier DA , Pollard S , McPhail M , Bubela T , Hanna TP , Ho C , Lim HJ , Chan K , Peacock SJ , Weymann D. (2022). A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.NPJ precision oncology. 6(1): 76.  
Published,
32. Lau TTY , Sefid Dashti ZJ , Titmuss E , Pender A , Topham JT , Bridgers J , Loree JM , Feng X , Pleasance ED , Renouf DJ , Schrader KA , Sun S , Ho C , Marra MA , Laskin J , Karsan A. (2022). The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.The Journal of molecular diagnostics : JMD. 24(6): 609-618.  
Published,
33. Lee VH , Adham M , Ben Kridis W , Bossi P , Chen MY , Chitapanarux I , Gregoire V , Hao SP , Ho C , Ho GF , Kannarunimit D , Kwong DL , Lam KO , Lam WKJ , Le QT , Lee AW , Lee NY , Leung TW , Licitra L , Lim DW , Lin JC , Loh KS , Lou PJ , Machiels JP , Mai HQ , Mesía R , Ng WT , Ngan RK , Tay JK , Tsang RK , Tong CC , Wang HM , Wee JT. (2022). International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.The Lancet. Oncology. 23(12): e544-e551.  
Published,
34. Ho C , Lim HJ , Regier DA. (2021). Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.JAMA network open. 4(8): e2120301.  
Published,
35. Naso JR , Banyi N , Al-Hashami Z , Zhu J , Wang G , Ionescu DN , Ho C. (2021). Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.Cancer treatment and research communications. 27: 100353.  
Published,
36. Soleimani M , Kollmannsberger C , Bates A , Leung B , Ho C. (2021). Patient-reported psychosocial distress in adolescents and young adults with germ cell tumours.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 29(4): 2105-2110.  
Published,
37. Ho C , Chan B , Cameron D , Shokoohi A , Regier DA , Lim H. (2021). Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment.JCO oncology practice. 17(12): e1923-e1929.  
Published,
38. Leung B , Shokoohi A , Bates A , Ho C. (2021). Patient-reported psychosocial needs and psychological distress predict survival in geriatric oncology patients.Journal of geriatric oncology. 12(4): 612-617.  
Published,
39. Hamilton SN , Tran E , Ho C , Berthelet E , Wu J , DeVries K , LaPointe V , Bowman A , Lagman M , Olson R. (2021). Patient-reported outcome measures in patients undergoing radiotherapy for head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 29(5): 2537-2547.  
Published,
40. Jain A , Huang R , Lee J , Jawa N , Lim YJ , Guron M , Abish S , Boutros PC , Brudno M , Carleton B , Cuvelier GDE , Gunaratnam L , Ho C , Adeli K , Kuruvilla S , Lajoie G , Liu G , Nathan PC , Rod Rassekh S , Rieder M , Waikar SS , Welch SA , Weir MA , Winkquist E , Wishart DS , Zorzi AP , Blydt-Hansen T , Zappitelli M , Urquhart B. (2021). A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol.Canadian journal of kidney health and disease. 8: 20543581211057708.  
Published,



41. Naso JR , Wang G , Banyi N , Derakhshan F , Shokoohi A , Ho C , Zhou C , Ionescu DN. (2021). Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma. *Annals of diagnostic pathology*. 50: 151590.  
Published,
42. Myers R , Brauer M , Dummer T , Atkar-Khattra S , Yee J , Melosky B , Ho C , McGuire AL , Sun S , Grant K , Lee A , Lee M , Yuchi W , Tammemagi M , Lam S. (2021). High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 16(11): 1850-1858.  
Published,
43. Wong SK , Alex D , Bosdet I , Hughesman C , Karsan A , Yip S , Ho C. (2021). MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy. *Lung cancer (Amsterdam, Netherlands)*. 154: 142-145.  
Published,
44. Adjei AA , Ignatius Ou SH , Ho C , Pujol JL , Mandrekar S , Stone E , Bezjak A , Camidge DR. (2021). Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 16(5): 706-708.  
Published,
45. Boucher A , Ezzat S , Hotte S , Rachinsky I , Rajaraman M , Ruether D , Wiseman SM , Brierley J , Ho C , Krzyzanowska M , Lamond N , Massicotte MH , Joseph S , Herscovitch K , Sikora L , Winquist E. (2021). Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. *Oral oncology*. 121: 105477.  
Published,
46. Wong SK , Hamm J , Shokoohi A , McGahan CE , Ho C. (2021). Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. *BMC cancer*. 21(1): 215.  
Published,
47. Pender A , Hughesman C , Law E , Kristanti A , McNeil K , Wong S , Tucker T , Bosdet I , Young S , Laskin J , Karsan A , Yip S , Ho C. (2020). EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes. *Translational lung cancer research*. 9(4): 1084-1092.  
Published,
48. Majounie E , Wee K , Williamson LM , Jones MR , Pleasance E , Lim HJ , Ho C , Renouf DJ , Yip S , Jones SJM , Marra MA , Laskin J. (2020). Fluorouracil Sensitivity in a Head and Neck Squamous Cell Carcinoma With a Somatic DPYD Structural Variant. *Cold Spring Harbor molecular case studies*. 6(1): a004713.  
Published,
49. Moore S , Leung B , Wu J , Ho C. (2020). Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients. *Radiation oncology (London, England)*. 15(1): 23.  
Published,
50. Naso JR , Wang G , Pender A , Wong SK , Zhu J , Ho C , Ionescu DN , Zhou C. (2020). Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. *Histopathology*. 76(3): 394-403.  
Published,
51. Shokoohi A , Berthelet E , Gill S , Prisman E , Sexsmith G , Tran E , White A , Wiseman SM , Wu J , Ho C. (2020). Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience. *Cureus*. 12(2): e7122.  
Published,

52. Smrke A , Leung B , Srikanthan A , McDonald M , Bates A , Ho C. (2020). Distinct Features of Psychosocial Distress of Adolescents and Young Adults with Cancer Compared to Adults at Diagnosis: Patient-Reported Domains of Concern. *Journal of adolescent and young adult oncology*. 9(4): 540-545.  
Published,
53. Robinson DAG , Snow S , Brade A , Ho C , Wheatley-Price P , Blais N , Cheema P , Swaminath A. (2020). Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations. *Cancer treatment and research communications*. 25: 100265.  
Published,
54. Moore S , Leung B , Wu J , Ho C. (2020). Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC. *JTO clinical and research reports*. 1(4): 100083.  
Published,
55. Moore S, Leung B, Wu J, Ho C. (2019). Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer. *Am J Clin Oncol*. 10: 1097. ,  
Refereed?: Yes
56. Ian Fraser, Shilo Lefresne, Jacqueline Regan, Eric Berthelet, Negar Chooback, Cheryl Ho, Robert Olson. (2019). Palliative thoracic radiotherapy near the end of life in lung cancer: a population-based analysis. *Lung Cancer*. 135: 97-103. ,
57. Ho C , Lefresne S , Liberman M , McGuire A , Palma D , Pender A , Snow S , Tremblay A , Myers R. (2019). Lung Cancer in Canada. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 14(7): 1128-1133.  
Published,
58. Lau SC , Chooback N , Ho C , Melosky B. (2019). Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. *Clinical lung cancer*. 20(5): e576-e583.  
Published,
59. Tsang ES, Shen Y, Chooback N, Ho C, Jones M, Renouf DJ, Lim H, Sun S, Yip S, Pleasance E, Ionescu DN, Mungall K, Kasaian K, Ma Y, Zhao Y, Mungall A, Moore R, Jones SJM, Marra M, Laskin J. (2019). Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. *Cold Spring Harb Mol Case Stud*. 1(5): 1. ,  
Refereed?: Yes
60. Leung B, Laskin J, Wu J, Bates A, Ho C. (2019). Assessing the Psychosocial Needs of Newly Diagnosed Patients with Non-Small Cell Lung Cancer: Identifying Factors Associated with Distress. *Psychooncology*. 28(4): 815-821.  
Published,
61. Srikanthan A , Leung B , Shokoohi A , Smrke A , Bates A , Ho C. (2019). Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience. *Sarcoma*. 2019: 5302639.  
Published,
62. Sara Moore, Bonnie Leung, Jonn Wu, Cheryl Ho. (2019). Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. *Journal of Thoracic Oncology*. 14: 1430-1439.  
Accepted,
63. My Linh Thibodeau, Melika Bonakdar, Eric Zhao, Karen L. Mungall, Caralyn Reisle, Wei Zhang, Morgan H. Bye, Nina Thiessen, Dustin Bleile, Andrew J. Mungall, Yussanne P. Ma, Martin Jones, Daniel J. Renouf, Howard J. Lim, Stephen Yip, Tony Ng, Cheryl Ho, Janessa Laskin, Marco Marra, Kasmintan A. Schrader, Steven J. M. Jones. (2018). Whole genome and whole transcriptome genomic profiling of a metastatic eccrineporocarcinoma. *Npg Precision Medicine*. 2(1): 8.  
Accepted,  
Refereed?: Yes

64. Benjamin Maas, Cheryl Ho, Sarah Hamilton, Doug Leedy, Eric Berthelet. (2018). Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma.Cureus. 10(7): e2971.  
Co-Author  
Published,  
Refereed?: Yes, Open Access?: Yes
65. Chooback N, Lefresne S, Lau SC, Ho C. (2018). CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization.J Oncol Pract. 14(10): e612-e620. ,  
Refereed?: Yes
66. Giambattista J, McVicar N, Hamilton S, Martin M, Maas B, Ho C, Wu J, Tran E, Hay J, Berthelet E. (2018). Magnetic Resonance Imaging Volumetry of Primary Nasopharyngeal Cancer in Patients Treated with Induction Gemcitabine and Cisplatin Followed by Concurrent Cisplatin and Volumetric Modulated Arc Therapy.Cureus. 10(9): e3296. ,  
Refereed?: Yes
67. Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. (2017). Phase I study of foretinibplus erlotinib in patients with previously treated advanced non-small cell lungcancer: Canadiancancertrials group IND.196. Oncotarget. 8(41): 68651-69662.  
Published,  
Refereed?: Yes
68. Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. (2017). Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Current Oncology. 4: 228-233.  
Last Author  
Published,  
Refereed?: Yes, Open Access?: No
69. Shaan Dudani, MB ChB; Xiaofu Zhu, MD; Daniel W Yokom, MD; Andrew Yamada; Cheryl Ho, MD; Jason R Pantarotto, MD; Natasha B Leighl, MD; Tinghua Zhang; Paul Wheatley-Price. (2017). Radicaltreatment of stage II non-small cell lung cancer with non-surgical approaches:A multi-institution report of outcomes.Clinical Lung Cancer. 19(1): e11-e18. ,
70. Chooback N, Shen Y, Jones M, Kasaian K, Martin M, Ng T, Thomson T, Marra M, Laskin J, Ho C. (2017). Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy.Current Oncology. 3: e251-e254.  
Last Author  
Published,  
Refereed?: Yes, Open Access?: No
71. Ho C, Siegfried J, Remo K, Laskin J. (2017). Adherenceto surveillance guidelines in resected NSCLC: Physician compliance and impacton outcomes. Lung Cancer. 112: 176-180.  
First Listed Author  
Published,  
Refereed?: Yes
72. Geller G, Laskin J, Cheung WY, Ho C. (2017). A retrospective review of themultidisciplinary management of medullary thyroid cancer: eligibility forsystemic therapy. Thyroid Research. 10: 6.  
Last Author,  
Refereed?: Yes
73. Jones MR, Lim H, Shen Y, Pleasance E, Ch'ng C, Reisle C, Leelakumari S, Zhao C, Yip S, Ho J, Zhong E, Ng T, Ionescu D, Schaeffer DF, Mungall AJ, Mungall KL, Zhao Y, Moore RA, Ma Y, Chia S, Ho C, Renouf DJ, Gelmon K, Jones SJM, Marra MA, Laskin J. (2017). Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Ann Oncol. 28(12): 3092-9097. ,  
Refereed?: Yes

74. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *Journal of Clinical Oncology*. 35(24): 2781-2789.  
Co-Author  
Published,  
Refereed?: Yes
75. Chuong Ho, Kelsey Seal, Charlene Argáez, Cheryl Ho. (2017). Treatments for locally advanced oropharyngeal cancer: a systematic review of clinical effectiveness and cost-effectiveness. *Canadian Agency for Drugs and Technologies in Health*. 1: 1-79.  
Last Author  
Published,  
Refereed?: Yes
76. Fred Hsu, MD; Alex De Caluwe, MD; David Anderson, MD; Alan Nichol, MD; Ted Toriumi, RTT; Cheryl Ho, MD. (2016). EGFR mutation status on brain metastases from non-small cell lung cancer. *Lung Cancer*. 96: 101-7.  
Published,  
Refereed?: Yes
77. Zibrik K, Laskin J, Ho C. (2016). . Integration of a nurse navigator into the triage process of patients with NSCLC: Creating systematic improvements in patient care. *Current Oncology*. 23(4): e280-3. ,
78. Michael Yan, BSc, Cheryl Ho, MD, Eric Winkvist, MD, MSc, Derek Jonker, MD, Daniel Rayson, MD, Larry Stitt, MSc, Sonya Tokmakejian, PhD, Mark D. Vincent, MD. (2016). Pre-treatment Serum Folate Levels and Toxicity Risk in Colorectal Cancer Patients Treated with 5-Fluorouracil and Folinic Acid. *Clin Colorectal Ca*. 16: 300-75. ,
79. Shaan Dudani, Natasha B. Leighl, Cheryl Ho, Jason R. Pantarotto, Xiaofu Zhu, Tinghua Zhang and Paul Wheatley-Price. (2016). Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): a survey of Canadian medical and radiation oncologists. *Lung Cancer*. 94: 74-80. ,
80. Ren Yuan, Andrew Yamada, Britta Weber and Cheryl Ho. (2016). Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. *J Neurooncol*. 127(3): 525-33. ,
81. Brandon S. Sheffield, Regan Fulton, Steve E Kalloger, Katy Milne, Georgia Geller, Martin Jones, Celine Jacquemont, Susanna Zachara, Eric Zhao, Erin Pleasance, Janessa Laskin, Steven JM Jones, Marco A Marra, Stephen Yip, Brad H Nelson, Allen M Gown, Cheryl Ho, Diana N. Ionescu. (2016). Investigation of biomarker testing methods for PD-1 axis inhibition in non-small cell lung cancer. *J Histochem Cytochem*. 64(10): 587-600. ,
82. Zibrik K, Laskin J, Ho C. (2016). . Implementation of a lung cancer nurse navigator enhances patient care and delivery of systemic therapy at the British Columbia Cancer Agency, Vancouver. *Journal of Oncology Practice*. 12(3): 344-349. ,
83. Ramsden K, Laskin J, Ho C. (2015). Adjuvant chemotherapy in resected Stage II NSCLC: Evaluating the impact of dose intensity and time to treatment. *Clinical Oncology*. 27(7): 394-400.  
Published,
84. Noonan, Krista L. MD; Ho, Cheryl MD; Laskin, Janessa MD; Murray, Nevin M. (2015). The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials. *Journal of Thoracic Oncology*. 10(11): 1523-1531. ,

85. 11. Bose P, Pleasance ED, Jones M, Shen Y, Ch'ng C, Reisle C, Schein JE, Mungall AJ, Moore R, Ma Y, Sheffield BS, Thomson T, Rasmussen S, Ng T, Yip S, Lee CW, Ho C, Laskin J, Marra MA, Jones SJ. (2015). Integrative genomic analysis of ghost cell odontogenic carcinoma. *Oral Oncology*. 51(9): e71-5. Published,
86. Barbara Melosky, Helen Anderson, Ronald L Burkes, Quincy Chu, Desiree Hao, Vincent Ho, Cheryl Ho, Wendy Lam, Christopher W Lee, Natasha B Leighl, Nevin Murray, Sophie Sun, Robert Winston, and Janessa J Laskin. (2015). The Pan Canadian Rash Trial: A Phase III, Randomized Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on EGFR-TKI Induced Skin Toxicities in Patients with Metastatic Lung Cancer. *JCO*. 34(8): 810. ,
87. Cheryl Ho, King Mong Tong, Katherine Ramsden, Diana N. Ionescu, Janessa Laskin. (2015). Histological classification of non-small cell lung cancer (NSCLC) over time: Reducing the rates of NSCLC – not otherwise specified (NOS). *Current Oncology*. 22(3): 164. Accepted,

## Book Chapters

1. Ho C, Lara PN, Gandara DR, Davies AM. Women in Lung Cancer: A Neglected Epidemic. *Elit L. Women and Cancer: Current Issues and Initiatives*. First Listed Author Published,
2. Ho C, Gautschi O, Davies M. Lung Cancer Vaccines. Pandya KJ, Brahmer JR, Hidalgo M. *Lung Cancer: Translational and Emerging Therapies*. First Listed Author Published,
3. Ho C, Davies AM, Lara PN, Gautschi O, Mack PC, Gumerlock PH, Gandara DR. Untargeted Use of Targeted Therapy: A Dilemma in NSCLC. Kaufman HL, Wadler S, Antman K. *Molecular Targeting in Oncology*. First Listed Author Published,
4. Wang Y, Ho C, Laskin, J. (2016). Management of Pulmonary Neuroendocrine Tumors. Kalemkerian GP, Donington JS, Gore EM, Ramalingam SS. *Handbook of Lung Cancer and Other Thoracic Malignancies*. Published, Demos Medical Publishing, United States of America

## Conference Publications

1. Cheryl Ho, Yu Yang Soon, Alan Nichol, Kristy Robledo Arjun Sahgal, Mark Pinkham, Barbara Melosky, Yiqing Huang, Ambika Parmar, Ben Solomon, Mitchell Liu, Ivan Weng Keong Tham, Adrian Sacher, Jeremy Chee Seong Tey, Ines Menjak, Cheng Nang Leong, David Shultz, Wee Yao Koh, Mark Doherty, Yvonne Ang, Jiali Low, Clement Yong, Mei Chin Lim, Ai Peng Tan, Chee Khoo Lee, Ross Soo, Shilo Lefresne, Fiona Hegi-Johnson. Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs. *World Conference on Lung Cancer*, , Conference Date: 2024/9 Paper
2. Fatima Usman, Shira Sabag, Eric Bhang, Marjan Kamali, Sam Pollard, Ali Hussein, Jason Ko-Leong, Curtis Hughesman, Deepu Alex, Patricia Demarco, Deirdre Weymann, Jonathan Loree, Karamjit Gill, Ying Wang, Janessa Laskin, Dean Regier, Howard Lim, Stephen Chia, Stephen Yip, Cheryl Ho. Application of tissue and liquid-based Next Generation Sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making. *ESMO*, , Conference Date: 2024/9 Poster

3. Sara M. Moore, Luna Jia Zhan, Deepro Chowdhury, Rebekah Rittberg, Marie Frédérique D'Amours, Stavroula Raptis, Deborah Akurang, Alexandra Lo, YongJin Kim, Fabian Yu, Stephanie Snow, Sara Kuruvilla, Andrea Fung, Vishal Navani, Jason Agulnik, David Dawe, Benjamin H. Lok, Geoffrey Liu, Cheryl Ho, Paul Wheatley-Price. Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the CANadian Small Cell lung cAncer DatabasE (CASCADE). ESMO, ,  
Conference Date: 2024/9  
Poster
4. Florence T.H. Wu, Marie D'Amours, Fatima Usman, Ali Hussein, Eric Bhang, Marjan Kamali Sarvestani, Christopher W. Lee, Cheryl Ho. Real-world prognostic & predictive implications of EORTC & MRS scores for immunotherapy and chemotherapy in pleural mesothelioma. World Conference on Lung Cancer, ,  
Conference Date: 2024/9  
Poster
5. Shira Sabag, Fatima Usman, Howard Lim, Curtis Hughesman, Deepu Alex, Eric Bhang, Alisha Bhimani, Patricia Demarco, Jiti Gill, Ali Hussein, Marjan Kamali-Sarvestani, Jason Ko-leong, Jonathan Loree, Samantha Pollard, Deirdre Weymann, Dean Regier, Stephen Chia, Stephen Yip, Cheryl Ho. Association between Genetic Information Provision and Decisional Conflict in Cancer Patients. ASCO Quality Care Symposium, ,  
Conference Date: 2024/9  
Poster
6. K.F. Fitzsimmons, C. Hughesman, M-F. D'Amours, D. Alex, D.N. Ionescu, B. Melosky, K. McNeil, C. Ho, S. Yip, J. Naso. Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes. World Conference on Lung Cancer, ,  
Conference Date: 2024/9  
Poster
7. M-F. D'Amours, M-H. Denault, J. Feng, J. Laskin, B. Leung, S. Sun, B. Melosky, M. Liu, H. Carolan, C. Ho. Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia. World Conference on Lung Cancer, ,  
Conference Date: 2024/9  
Poster
8. Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, James T. Topham, Robert Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Carl J. Brown, Sharlene Gill, Hagen F. Kennecke, Derek J. Jonker, Eric X. Chen, Daniel J. Renouf, Chris J. O'Callaghan, Jonathan M. Loree. Clonal hematopoiesis of indeterminate potential (CHIP): treatment outcomes and adverse events in patients with solid tumors. ASCO, ,  
Conference Date: 2024/6  
Poster
9. JJ Nunez, B Leung, R Ng, C Ho, A Bates. Predicting supportive care needs using natural language processing. MASCC/AFSOS/ISOO, ,  
Conference Date: 2024/6  
Paper
10. F.T.H.Wu, S. Yip, F. Usman, S. Sabag, C. Hughesman, T. Ng, D. Alex, K.E. Khoo, N.A. Bosma, J. Laskin, H. Lim, S.K. Chia, J. Ko-leong, S. Pollard, D. Weymann, P. Demarco, D.A. Regier, N. Chau and C. Ho. Comprehensive genomic characterization of thyroid cancers: Real-world implementation and impact on clinical decisions. Multidisciplinary head and neck cancers symposium, ,  
Conference Date: 2024/2  
Poster

11. Arman Gorji, Mahdi Hosseinzadeh, Ali Fathi Jouzdani, Nima Sanati, Fereshteh Yousefi Rizi, Sara Moore, Bonnie Leung, Cheryl Ho, Isaac Shiri, Arman Rahmim, and Mohammad R. Salmanpour. Region-of-Interest and Handcrafted vs. Deep Radiomics Feature Comparisons for Survival Outcome Prediction: Application to Lung PET/CT Imaging. IEEE Nuclear Science Symposium, Medical Imaging Conference, and Room-Temperature Semiconductor Detectors Symposium, ,  
Conference Date: 2023/10  
Poster
12. J. Connor Wells, Monica M. Mullin, Janessa Laskin, Barbara Melosky, Cheryl Ho, Ying Wang, Sophie Sun. Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib. ESMO, ,  
Conference Date: 2023/10  
Poster
13. Petros Christopoulos, Simon Ekman, Florian Guisier, Cheryl Ho, Miriam Blasi, Hans Brunnstromm, Jelena Cvetkovic, Daniel Kazdal, Jonas Kuon, Felix Haglund de Flon, Albrecht Stenzinger, Selina Wong, Anthony Hatswell, Thomas Mclean, Suzanne Bergman, Katrin Orlowski, Aurora O'Brate, Helene Vioix, Michael Thomas. TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION. ESMO, ,  
Conference Date: 2023/10  
Poster
14. F. Al Agha, S. Raptis, L.J. Zhan, S.H. Barghout, D. Patel, M.C. Brown, W. Xu, C. Ho, W. Cheung, D. Dawe, S. Banerji, S. Kuruvilla, P. Cheema, I. Menjak, R. Burkes, K. Jao, A. Fung, N. Blais, J. Agulnik, N. Bouchard, L. Galvis, R.A. Juergens, P. Wheatley-Price, S. Moore, S. Snow, G. Liu. CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study. World Conference on Lung Cancer, ,  
Conference Date: 2023/9  
Paper
15. Wheatley-Price, V. Navani, A. Pabani, B. Routy, S. Snow, M-H. Denault, Y. Kim, I. Syed, N. Devost, D. Hui, P. Arora, R. Velummailum, A. Springford, C. McKibbin, C. Ho. Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study. World Conference on Lung Cancer, ,  
Conference Date: 2023/9  
Paper
16. Florence T.H. Wu, Eric Bhang, Marjan Kamali Sarvestani, Christopher W. Lee, Cheryl Ho. Impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma. World Conference on Lung Cancer, ,  
Conference Date: 2023/9  
Poster
17. Eric Bhang, Stephen Yip, Marjan Kamali Sarvestani, Fatima Usman, Deepu Alex, Tony Ng, Barbara Campling, Krista Noonan, Ann Tan, Sunil Parimi, Janessa Laskin, Howard Lim, Steven Chia, Jason KoLeong, Shira Sabag, Patricia Demarco, Alisha Bhimani, Samantha Pollard, Deirdre Weymann, Dean Regier, Cheryl Ho, Nicole Chau. Real World NGS in Patients with Head and Neck Squamous Cell Carcinoma. American Head & Neck Society, ,  
Conference Date: 2023/6  
Paper
18. A. Gorji, A. Fathi Jouzdani, N. Sanati, M. Hosseinzadeh, A. Mahboubisarighieh, S. M. Rezaei, M. Maghsudi, S. Moore, B. Leung, C. Uribe, C. Ho, A. Rahmim, M. R. Salmanpour. PET-CT fusion based outcome prediction in lung cancer using deep and handcrafted radiomics features and machine learning. Society of Nuclear Medicine and Molecular Imaging, ,  
Conference Date: 2023/6  
Poster

19. M. R. Salmanpour, M. Hosseinzadeh, N. Sanati, A. Fathi Jouzdani, A. Gorji, A. Mahboubi, M. Maghsudi, S. M. Rezaeijo, S. Moore, B. Leung, C. Uribe, C. Ho, A. Rahmim. Tensor deep versus Radiomics features: lung cancer outcome prediction using hybrid machine learning systems. Society of Nuclear Medicine and Molecular Imaging, ,  
Conference Date: 2023/6  
Poster
20. Cheryl Ho, Florence Wu, Michael Humphreys, Bal Johal, Janessa Laskin, Sanjay Rao, Sara K. Taylor, Ying Wang, Christopher W. Lee. Ipilimumab plus nivolumab for advanced mesothelioma: Implementation into clinical practice Poster. International Mesothelioma Interest Group, Lille, France,  
Conference Date: 2023/6  
Poster
21. John-Jose Nunez, Bonnie Leung, Cheryl Ho, Raymond T. Ng, Alan Bates. Predicting which cancer patients will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing. ASCO, Chicago, United States of America,  
Conference Date: 2023/6  
Poster
22. Marjan Kamali, Stephen Yip, Eric Bhang, Fatima Usman, Deepu Alex, Tony Ng, Janessa Laskin, Howard Lim, Stephen Chia, Jason Ko-Leong, Shira Sabag, Sam Pollard, Deirdre Weymann, Patricia Demarco, Alisha Bhimani, Dean Regier, Nicole Chau, Cheryl Ho. Molecular characterization of salivary cancers: Patterns of genomic alterations and impact on therapeutic choices.American Head & Neck Society, ,  
Conference Date: 2023/6  
Paper
23. Arman Rahmim; Amirhosein Toosi; Mohammad R. Salmanpour; Natalia Dubljevic; Ian Janzen; Isaac Shiri; Ren Yuan; Cheryl Ho; Habib Zaidi; Calum MacAulay; Carlos Uribe; Fereshteh Yousefirizi.Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features.IEEE Nuclear Science Symposium, Medical Imaging Conference and Room Temperature Semiconductor Detector Conference, ,  
Conference Date: 2022/11  
Paper
24. Rebekah Rittberg, Lauren Jones, Bonnie Leung, Aria Shokoohi, D N Ionescu, Alexandra Pender, Ren Yuan, Selina K. Wong, Zamzam Salam Al-Hashami, Ying Wang, Cheryl Ho. Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world. ASCO Quality Care Symposium, ,  
Conference Date: 2022/9  
Poster
25. C. Ho, S. Wong, A. Hatswell, R. Slater, H. Vioix, C. Chouaid.Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice. ESMO, ,  
Conference Date: 2022/9  
Poster
26. Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1  $\geq$  50%: 3 weekly compared to 6 weekly dosing.ESMO, ,  
Conference Date: 2022/9  
Poster



27. Jamie Feng, Marie-Hélène Denault, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky. PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer.ESMO, ,  
Conference Date: 2022/9  
Poster
28. Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky. Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression.ESMO, ,  
Conference Date: 2022/9  
Poster
29. Fatima Usman, Rebekah Rittberg, Howard John Lim, Eric Bhang, Brandon Chan, Deepu Alex, Stephen K.L. Chia, Karamjit Gill, Jenny J. Ko, Jason KoLeong, Janessa J. Laskin, Jonathan M. Loree, Barbara L. Melosky, Mehrnoosh Pauls, Samantha Pollard, Ying Wang, Deirdre Weymann, Stephen Yip, Dean A Regier, Cheryl Ho. Patient-reported outcomes in a linguistically diverse cancer population: Addressing barriers to access. ASCO Quality Care Symposium, ,  
Conference Date: 2022/9  
Poster
30. Rebekah Rittberg, Bonnie Leung, Zamzam Al Hashimi, Cheryl Ho. Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer. WCLC, ,  
Conference Date: 2022/8  
Poster
31. Ren Yuan, Ian Janzen, Cheryl Ho, Barb Melosky, Jessica Li, Stephen Lam, Calum MacAulay. **A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1** . WCLC, ,  
Conference Date: 2022/8  
Poster
32. R. Yuan, A. Silver, M. Ye, C. Ho, J. Zhang, Y. Wang, L. Wu, M. Martin, S. Lam, C. MacAulay, B. Melosky. Combination of baseline disease and smoking pack-years can guide the 1st-line treatment decision in advanced NSCLC with high PD-L1 expression. WCLC, ,  
Conference Date: 2022/8  
Poster
33. Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al Hashimi, Ying Wang, Cheryl Ho. Toxicity of Tyrosine Kinase Inhibitors after Immune Checkpoint Inhibitors in Incurable Non-Small Cell Lung Cancer. WCLC, ,  
Conference Date: 2022/8  
Poster
34. Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al Hashimi, Ying Wang, Cheryl Ho. “Long Responders” Compared to “Non-Responders” to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer. WCLC, ,  
Conference Date: 2022/8  
Poster
35. Sara Mieko Moore, Luna Jia Zhan, Geoffrey Liu, Rebekah Rittberg, Devalben Patel, Deepro Chowdhury, Bonnie Leung, Sierra Ching Lein Cheng, Mathieu Mckinnon, Khaleeq Khan, Jason Agulnik, Winson Y Cheung, David Dawe, Andrea Fung, Stephanie Snow, Victor Cohen, Michael Yan, Benjamin H Lok, Paul Wheatley-Price, Cheryl Ho. Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE). WCLC, ,  
Conference Date: 2022/8  
Poster

36. Sara Mieko Moore, Luna Jia Zhan, Geoffrey Liu, Rebekah Rittberg, Devalben Patel, Deepro Chowdhury, Bonnie Leung, Sierra Ching Lein Cheng, Mathieu Mckinnon, Khaleeq Khan, Stephanie Snow, Andrea Fung, David Dawe, Winson Y Cheung, Jason Agulnik, Michael Yan, Victor Cohen, Paul Wheatley-Price, Cheryl Ho, Benjamin H Lok. Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE). WCLC, ,  
Conference Date: 2022/8  
Poster
37. Sara Mieko Moore, Luna Jia Zhan, Geoffrey Liu, Rebekah Rittberg, Devalben Patel, Deepro Chowdhury, Bonnie Leung, Sierra Ching Lein Cheng, Mathieu Mckinnon, Khaleeq Khan, Jason Agulnik, Andrea Fung, Winson Y Cheung, Stephanie Snow, David Dawe, Victor Cohen, Michael Yan, Cheryl Ho, Benjamin H Lok, Paul Wheatley-Price. The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration. WCLC, ,  
Conference Date: 2022/8  
Poster
38. R Rittberg, B Leung, Z Al-hashami, C Ho. Real World Patient Eligibility for Lurbinectedin/Doxorubicin in Small Cell Lung Cancer. European Lung Cancer Conference, ,  
Conference Date: 2022/5  
Poster
39. Anthony T.C. Chan, Victor Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Cheryl Ho, Mohamed Amir Shah Abdul Aziz, Quan Sing Ng, Chia-Jui Yen, Nopadol Soparattanapaisarn, Roger Kai-Cheong Ngan, Swee Kiong Kho, Ramona Swaby, Sanatan Saraf, Joy Ge, Jianda Yuan, Lillian L. Siu. Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase 3 KEYNOTE-122. ESMO Immuno-Oncology Congress, ,  
Conference Date: 2021/12  
Poster
40. Dr. Cheryl Ho, Dr. Samantha Pollard, Deirdre Weymann, Dr. Howard Lim, Dr. Stephen Yip, Dr. Deepu Alex, Dr. Dean Regier. PRecision Oncology Evidence Development in Cancer Treatment PREDiCT: From Theory to Clinical Practice. CADTH Symposium, ,  
Conference Date: 2021/11  
Paper
41. Anthony T.C. Chan, Victor Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Cheryl Ho, Mohamed Amir Shah Abdul Aziz, Quan Sing Ng, Chia-Jui Yen, Nopadol Soparattanapaisarn, Roger Kai-Cheong Ngan, Swee Kiong Kho, Ramona Swaby, Sanatan Saraf, Joy Ge, Jianda Yuan, Lillian L. Siu. Results of KEYNOTE-122: a Phase 3 Study of Pembrolizumab Monotherapy vs Chemotherapy for Platinum-Pretreated, Recurrent or Metastatic Nasopharyngeal Carcinoma. ESMO, ,  
Conference Date: 2021/9  
Paper
42. Bonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina Wong, Ying Wang, Jonn Wu, Cheryl Ho. Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults. ASCO Quality Care Symposium, ,  
Conference Date: 2021/9  
Poster
43. Sara Moore, Jason Agulnik, Gwyn Bebb, David Dawe, Anifat Elegbede, Andrea Fung, Cheryl Ho, Geoff Liu, Benjamin Lok, Stephanie Snow and Paul Wheatley-Price. The CANadian Small Cell lung cancer Database (CASCaDe): A Multi-institutional Real-World Evidence Collaboration. WCLC, ,  
Conference Date: 2021/9  
Poster

44. M. Denault,  
S. Kuang  
, A. Shokoohi  
, B. Leung,  
M. Liu,  
J. Laskin,  
T. Zhang,  
B. Melosky,  
C. Ho,  
E. Berthelet,  
S. Sun. Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2  
versus 4 Weeks. WCLC, ,  
Conference Date: 2021/9  
Poster
45. V.Anagnostou, C.Ho, P.Wheatley-Price, S.Laurie, J.Taylor, A.Sacher. J.Brahmer, L.Gallinaro, K.Ding,  
J.Dancey. A biomarker-directed, multi-center phase II study of molecular response adaptive immuno-  
chemotherapy in lung cancer (CRI-CCTG-0002/BR.36, NCT04093167). WCLC, ,  
Conference Date: 2021/9  
Poster
46. Timothy Kong, Alan Nichol, Cheryl Ho, Alexander Benny, Negar Chooback, Ian Fraser, Lovedeep Gondara,  
Shilo Lefresne. Population based analysis of outcomes for patients with brain metastases from EGFR  
mutation positive NSCLC treated with TKI alone or in combination with radiotherap. CARO, ,  
Conference Date: 2021/9  
Poster
47. Leung B, Shokhoohi A, Al-Hashami Z, Moore S, Pender A, Wong S, Wang Y, Wu J & Ho C. Real world  
trends in treatment patterns for patients with advanced NSCLC: Comparing changes between younger and  
older adults. WCLC, ,  
Conference Date: 2021/9  
Paper
48. 28. Shokoohi A, Ho C, Wiseman SM, Wu J, Gill S, White A, Prisman E, Hamilton S, Tran E, Berthelet E.  
Adherence to the American Thyroid Association Guidelines in the Management of Differentiated Thyroid  
Cancer: Impact on Survival Outcomes.CARO, ,  
Conference Date: 2021/9  
Poster
49. Ian Janzen, Rohan Abraham, Saeed Seyyedi, Cheryl Ho, Barb Melosky, Monty Martin, Stephen Lam, Ren  
Yuan, Calum Macaulay. Predicting Treatment Response to 1st line Pembrolizumab in Advanced Non-Small  
Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression. WCLC, ,  
Conference Date: 2021/9  
Poster
50. Selina Wong, Deepu Alex, Ian Bosdet, Curtis Hughesman, Aly Karsan, Stephen Yip, Cheryl Ho. MET Exon  
14 Skipping Mutation Positive NSCLC: A population-based cohort.WCLC, ,  
Conference Date: 2021/1  
Poster
51. Julia R. Naso, Norbert Banyi, Zamzam Al-Hashami, Gang Wang, Diana N. Ionescu and Cheryl Ho.  
Discordance on Repeat PD-L1 Testing in Non-Small Cell Lung Carcinoma.WCLC, ,  
Conference Date: 2021/1  
Poster

52. Stephen Lam MD, Renelle Myers MD, Sukhinder Atkar-Khattra BSc, John Yee MD, Kyle Grant MD MSc, Anna L. McGuire MD MSc Alexander Lee MD MSc, Barbara Melosky MD, Cheryl Ho MD, Anne DyBuncio BSc, Martin Tammemagi PhD. A Multiplex Plasma Protein Panel for Detection of Lung Cancer in Ever Smokers Not Currently Eligible for Screening. WCLC, ,  
Conference Date: 2021/1  
Poster  
Refereed?: Yes
53. Shelley Kuang, Mitchell Liu, Cheryl Ho, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Barbara Melosky. Overall survival by PD-L1 status in stage III NSCLC following implementation of durvalumab: The real-world application of PACIFIC. WCLC, ,  
Conference Date: 2021/1  
Poster  
Refereed?: Yes
54. J. Li, J. Zhang, C. Ho, R. Myers, C. Mar, M. Martin, B. Melosky, S. Lam, R. Yuan. Regression of the Ground Glass Component in Patients with Multifocal Primary Lung Cancers Receiving Pembrolizumab. WCLC, ,  
Conference Date: 2021/1  
Poster  
Refereed?: Yes
55. Leung B, Wong S, Malli K & Ho C. End of life health resource utilization for limited English proficient patients with advanced NSCLC. WCLC, ,  
Conference Date: 2021/1  
Paper
56. Zamzam Al-hashami, Selina Wong, Aria Shokoohi, Alexandra Pender, Julia Naso, Diana Ionescu, Ren Yuan, Ying Wang, Cheryl Ho. Treatment past progression with second line nivolumab in advanced stage NSCLC. WCLC, ,  
Conference Date: 2021/1  
Poster  
Refereed?: Yes
57. Bonnie Leung, Selina Wong, Kiran Malli, Cheryl Ho. Access to palliative care services for limited English proficient patients with advanced NSCLC. ASCO Quality Care Symposium, ,  
Conference Date: 2020/10  
Poster  
Refereed?: Yes
58. 36. Brandon Chan, David Cameron, Aria Shokoohi, Dean Regier, Howard Lim, Cheryl Ho. Readiness of health care systems to generate RWE: Frequency of radiographic imaging of metastatic disease during first line systemic therapy.ASCO Quality Care Symposium, ,  
Conference Date: 2020/10  
Poster  
Refereed?: Yes
59. 39. Shelley Kuang, Mitchell Liu, Cheryl Ho, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Barbara Melosky. Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC. ESMO, ,  
Conference Date: 2020/9  
Poster  
Refereed?: Yes, Invited?: No
60. Aria Shokoohi, Sara Moore, Alexandra Pender, Zamzam Al-hashami, Selina Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho. Effect of Current Treatment Evolution in Advanced NSCLC on Overall Survival in the Real World.ESMO, ,  
Conference Date: 2020/9  
Poster

61. G. Geller, J. Laskin, W. Cheung, C. Ho. A retrospective review of the multidisciplinary management of medullary thyroid cancer. CAMO, ,  
Conference Date: 2016/4  
Poster
62. Smith AD, Abou Elkassem A, Allen B, Mresh R, Khalaf A, Farag A, Lirette S, Shrestha Y, Williams D, Stevens R, Al-Hawary M, Chamarthi S, Chauhan A, Chernyak V, Clark T, Cox K, Digumarthy S, Ehieli W, Ferguson D, Gaballah A, Galgano S, Gandhi D, Lee S, Lee S, Mervak B, Mittal P, Murphy P, Nandwana S, O'Connor S, Patel N, Roda M, Surabhi V, Trace A, Wasnik A, Yacoub J, Zidan A, Anderson MD, Arend R, Brem EA, Dayyani F, Gao X, Goyal G, Hari P, Ho C, Henegan JC, Kratzke R, Meredith RF, McDonald A, Mooradian MR, Leath CA, Lou E, Narkhede M, Nandagopal Asha Nayak L, Paluri R, Rao A, Stringer-Reasor EM, Willey C, Yee D. (2020). Comparative effectiveness of AI-assisted vs. standard of care methods in advanced cancer longitudinal response evaluation in a multi-institutional study. ASCO, ,  
Conference Date: 2020/6  
Poster  
Co-Author
63. Parneet Cheema, William Evans, Ronald Burkes, Randeep Sangha, Cheryl Ho, Paul Wheatley-Price, Darryl Boehm, Jaya Venkatesh, Susan Walisser, Daniel Grima, Daniel Moldaver, Manjusha Hurry. (2019). Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model. ESMO, ,  
Conference Date: 2019/10  
Poster  
Co-Author  
Published
64. S Wong, J Hamm, A Shohooki, C McGahan, C Ho. (2019). Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage. ESMO, ,  
Conference Date: 2019/10  
Poster  
Last Author  
Published
65. Alannah Smrke, Bonnie Leung, Alan Bates, Amirrtha Srikanthan, Cheryl Ho. (2019). Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia. ESMO, ,  
Conference Date: 2019/10  
Poster  
Last Author  
Published
66. A. Pender, C. Hughesman, E. Law, A. Kristanti, K. McNeil, T. Tucker, I. Bosdet, S. Young, J. Laskin, A. Karsan, S. Yip, C. Ho. (2019). EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease. WCLC, ,  
Conference Date: 2019/9  
Poster  
Last Author  
Published
67. S. Moore, B. Leung, J. Wu, C. Ho. (2019). Survival Outcomes of Salvage Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. WCLC, ,  
Conference Date: 2019/9  
Poster  
Last Author  
Published

68. Alexandra Pender, Curtis Hughesman, Elaine Law, Amadea Kristanti, Kelly McNeil, Tracy Tucker, Ian Bosdet, Sean Young, Janessa J. Laskin, Aly Karsan, Stephen Yip, Cheryl Ho. (2019). Quantification of circulating free and circulating tumour DNA in pre-treated EGFR mutant NSCLC informs patient outcomes. ASCO, ,  
Conference Date: 2019/6  
Poster  
Last Author  
Published
69. Zamzam Al-Hashami, Bonnie Leung, Howard Lim, Alan Bates, Cheryl Ho. (2019). The Impact of psychosocial distress on survival in patients diagnosed with gastrointestinal (GI) malignancies. ASCO GI, ,  
Conference Date: 2019/2  
Poster  
Last Author  
Published
70. Maryam Soleimani, Bonnie Leung, Christian Kollmannsberger, Alan Bates, Cheryl Ho. (2019). Patient-reported psychosocial distress in adolescents and young adults with germ cell tumors. ASCO GU, ,  
Conference Date: 2019/2  
Poster  
Last Author  
Published
71. Srikanthan A, Leung B, Shokoohi A, Smrke A, Rennie H, Bates A and Ho C. (2018). Psychosocial Needs and Distress Scores Among Newly Diagnosed AYA Sarcoma Patients. Global Adolescent and Young Adult Cancer Congress, ,  
Conference Date: 2018/12  
Poster  
Last Author  
Published
72. Srikanthan A, Leung B, Shokoohi A, Smrke A, Rennie H, Bates A and Ho C. (2018). Depression and anxiety among newly diagnosed sarcoma patients. Connective Tissue Oncology Society Annual Meeting, ,  
Conference Date: 2018/11  
Poster  
Last Author  
Published
73. Sara Moore, Bonnie Leung, Alan Bates, Cheryl Ho. (2018). Social Isolation: impact on treatment and survival in patients with advanced cancer. ASCO Palliative and Supportive Care in Oncology Symposium, ,  
Conference Date: 2018/10  
Poster  
Last Author  
Published
74. Dr. Alan Bates, MD, PhD, Ms. Bonnie Leung, MN-NP(F), Dr. Amirrtha Srikanthan, MD, Ms. Heather Rennie, MA, MSc, Ms. Gina MacKenzie, MSW, Mr. Aria Shokoohi, BSc, Dr. Janessa Laskin, MD, Dr. Jonn Wu, MD, Dr. Cheryl Ho, MD. (2018). All the lonely people: Social isolation and cancer-related mortality. Canadian Psychiatric Association conference, ,  
Conference Date: 2018/9  
Paper  
Last Author  
Published

75. Zamzam Al-Hashami, Bonnie Leung, Janessa Laskin, Jonn Wu, Heather Rennie, Alan Bates, Cheryl Ho,. (2018). The impact of socioeconomic status and geographic location on palliative chemotherapy uptake in patients with metastatic non-small cell lung cancer treated in British Columbia.WCLC, ,  
Conference Date: 2018/9  
Paper  
Last Author  
Published
76. Sarah Hamilton, Eric Tran, Vincent Lapointe, Julianna Caon, Angela Bowman, Cindy Reynolds, Cheryl Ho, Minette Lagman, Erika Brown, Robert Olson. (2018). Patient Reported Outcomes during Radiotherapy for Head and Neck Cancer: A Prospective Outcomes and Support Initiative. CARO, ,  
Conference Date: 2018/9  
Poster  
Co-Author  
Published
77. C. Ho, B. Leung, H. Rennie, J. Laskin, J. Wu, A. Bates. (2018). Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location. ESMO, ,  
Conference Date: 2018/9  
Poster  
First Listed Author  
Published
78. Cheryl Ho, Arun Agha, Natalie Devost, Ryan Walton, Sunita Ghosh, Quincy Chu. (2018). Biopsy on Progression in EGFR Mutation Positive (EGFRm) Advanced Non-Small Cell Lung Cancer (aNSCLC) patients (pts) - A Canadian Experience. Poster. ESMO, ,  
Conference Date: 2018/9  
Poster  
First Listed Author  
Published
79. Sara Moore, Bonnie Leung, Jonn Wu, Cheryl Ho. (2018). Optimal therapy of stage III NSCLC: the role of surgery in the era of immunotherapy. WCLC, ,  
Conference Date: 2018/9  
Poster  
Last Author  
Published
80. Bonnie Leung, Aria Shokoohi, Jonn Wu, Janessa Laskin, Heather Rennie, Alan Bates, Cheryl Ho. (2018). Social isolation increases psychological distress in patients with NSCLC.WCLC, ,  
Conference Date: 2018/9  
Paper  
Last Author  
Published
81. J]Cressman S, Stuart James Peacock, Alain Tremblay, Cheryl Ho, Martin Tammemägi, Stephen Lam. (2018). Adherence Rates and Budget Impact of High-Risk Screening in Canada: Evidence from the Pan-Canadian Early Detection of Lung Cancer Study. WCLC, ,  
Conference Date: 2018/9  
Poster  
Co-Author  
Published

82. Renelle Myers, Michael Brauer, Sim Ladhar, Sukhinder Atkar-Khattra, John Yee, Cheryl Ho, Anna McGuire, Kyle Grant, Alexander Lee, Barbara Melosky, Sophie Sun, Martin Tammemagi, Stephen Lam. (2018). Strong Effect Of Outdoor Air Pollution in Female Never Smokers With Lung Cancer. WCLC, ,  
Conference Date: 2018/9  
Paper  
Co-Author  
Published
83. Huget-Penner, S, Ho C, Gill, S. (2018). Sorafenib Therapy For Resistant Hypercalcemia Due To Metastatic Parathyroid Carcinoma. ENDO, ,  
Conference Date: 2018/6  
Poster  
Co-Author  
Published
84. Bonnie Leung, Aria Shokoohi, Alan Bates, Cheryl Ho. (2018). Patient-reported psychosocial needs and psychological distress and the influence on survival in geriatric oncology patients. ASCO, ,  
Conference Date: 2018/6  
Poster  
Last Author  
Published
85. Alannah Smrke, Bonnie Leung, Aria Shokoohi, Amirrtha Srikanthan, Heather Rennie, Alan Bates, Cheryl Ho. (2018). Identifying support needs at initial oncologic consultation for patients with sarcoma treated in British Columbia using the Canadian Problem Checklist. International Sarcoma Symposium, ,  
Conference Date: 2018/6  
Poster  
Last Author  
Published
86. A.T. Bates, B. Leung, A. Srikanthan, H. Rennie, G. MacKenzie, A. Shokoohi, J. Laskin, J. Wu, C. Ho. (2018). Psychosocial variables and cancer mortality. Canadian Association of Psychosocial Oncology. CAPO, ,  
Conference Date: 2018/5  
Paper  
Last Author  
Published
87. Shokoohi A., Berthelet E., Sexsmith G., Wu J., Gill S., White A., Prisman E., Tran E., Wiseman S.M., Ho C. (2017). A population based review of salvage surgery, radioactive iodine, external beam radiation and systemic therapy for management of recurrent differentiated thyroid cancer. ATA, ,  
Conference Date: 2017/10  
Poster  
Last Author  
Published
88. Berthelet E., Shokoohi A., Wu J. Gill S., White A. Sexsmith G., Prisman E., Tran E., Wiseman S.M., Ho C. (2017). Management of differentiated thyroid cancer in accordance with the American Thyroid Association Guidelines: Impact on patient disease free survival and overall survival outcomes. ATA, ,  
Conference Date: 2017/10  
Poster  
Last Author  
Published



89. Bonnie Leung, Hiten Naik, Janessa Laskin, Jonn Wu, Regina McKenzie, Alan Bates and Cheryl Ho. (2017). Assessing the psychosocial needs of lung cancer patients: Patient-identified gaps in care. WCLC, ,  
Conference Date: 2017/9  
Poster  
Last Author  
Published
90. Sally C. Lau, Negar Chooback, Cheryl Ho, Barbara Melosky. (2017). Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC. WCLC, ,  
Conference Date: 2017/9  
Poster  
Co-Author  
Published
91. Negar Chooback, Sally C. Lau, Shilo Lefresne, Cheryl Ho. (2017). Metastases in EGFR mutation positive #EGFRm# NSCLC patients: the prognostic relevance of presenting symptoms. WCLC, ,  
Conference Date: 2017/9  
Poster  
Last Author  
Published
92. F. Lacroix-Poisson, F. Benard, D. Wilson, M.J. Adam, D. Yapp, C. Ho, J. Laskin. (2017). Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab. WCLC, ,  
Conference Date: 2017/9  
Poster  
Co-Author  
Published
93. Negar Chooback, Sally C. Lau, Shilo Lefresne, Cheryl Ho. (2017). CNS metastases in EGFR mutation positive NSCLC: Impact on health resource utilization. WCLC, ,  
Conference Date: 2017/9  
Poster  
Last Author  
Published
94. Sara Moore, Bonnie Leung, Jonn Wu, Cheryl Ho. (2017). Stage by stage comparison of radiotherapy versus surgery in NSCLC: The influence of prognostic factors on survival outcome. WCLC, ,  
Conference Date: 2017/9  
Poster  
Last Author  
Published
95. Sara Moore, Bonnie Leung, Jonn Wu, Aria Shokoohi, Cheryl Ho. (2017). Recurrent versus de novo metastatic NSCLC: Impact on outcomes. ASCO, ,  
Conference Date: 2017/6  
Poster  
Last Author  
Published

96. 37. Robert L. Ferris, George Blumenschein, Jr., Kevin Harrington, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Everett Vokes, Maura Gillison, Caroline Even, Cheryl Ho, Makato Tahara, Robert Haddad, Mark Lynch, Manish Monga, Somnath Bandyopadhyay, Omar Jabado, Henry Kao. (2017). Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141. AACR, ,  
Conference Date: 2017/4  
Poster  
Co-Author  
Published
97. Robert L. Ferris, George Blumenschein, Kevin Harrington, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas, Lisa Licitra, Stefan Kasper, Caroline Even, Francis Worden, Nabil Saba, Everett Vokes, Cheryl Ho, Fernando Concha-Benavente, Danielle Greenawalt, Chelsea Jin, Mark Lynch, Makato Tahara, Robert Haddad, Manish Monga, Henry Kao, Maura Gillison. (2017). Tumor-associated immune cell (TAIC) PD-L1 expression and peripheral cytokine profiling: Analyses from CheckMate 141. AACR, ,  
Conference Date: 2017/4  
Poster  
Co-Author  
Published
98. Cheryl Ho, Jennifer Siegfried, Karen Remo, Janessa Laskin. (2016). Adherence to Surveillance Guidelines in Resected NSCLC: Physician Compliance and Impact on Outcomes. WCLC, ,  
Conference Date: 2016/9  
Poster  
First Listed Author  
Published
99. J. Laskin, C. Ho, Y. Shen, M. Jones, K.A. Gelmon, H. Lim, D.J. Renouf, S. Yip, A. Tinker, K. Khoo, C. Lohrisch, S. Chia, B. Deol, K. Schrader, Y. Ma, R. Moore, A. Mungall, S. Jones, M. Marra. (2016). Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers. ESMO, ,  
Conference Date: 2016/9  
Paper  
Co-Author
100. Ying Wang, Cheryl Ho, Kevin Bushell, Solomon Vandt, Ian Bosdet, Lucas Swanson, Janessa Laskin, Sophie Sun, Barbara Melosky, Nevin Murray, Ryan Morin, Aly Karsan, Hagen Kennecke. (2016). Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity. WCLC, ,  
Conference Date: 2016/9  
Poster  
Co-Author  
Published
101. Shaan Dudani, Xiaofu Zhu, Daniel W. Yokom, Andrew Yamada, Cheryl Ho, Jason Pantarotto, Natasha B. Leighl, Tinghua Zhang, Paul Wheatley-Price. (2016). Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes. WCLC, ,  
Conference Date: 2016/9  
Poster  
Co-Author

102. J. Laskin, D. Ha, T. Chan, A. Fok, K.A. Gelmon, A. Charters, R. Yoshizawa, S. Struve<sup>2</sup>, C. Ho, D. Renouf, H. Lim, C. Simmons, S. Taylor, A. Tinker, J. McGhie, S. Jones, M. Marra, P. Chow-White. (2016). Clinicians identify high need to increase their genomic literacy to applied cancer genomics. ESMO, ,  
Conference Date: 2016/9  
Poster  
Co-Author  
Published
103. Michael Yan, Mark David Vincent, Cheryl Ho, Eric Winkvist, Derek J. Jonker, Daniel Rayson. (2016). Pre-treatment serum folate levels and toxicity in colorectal cancer patients treated with 5-fluorouracil and folinic acid. ASCO GI, ,  
Conference Date: 2016/2  
Poster  
Co-Author  
Published
104. Kelly Zibrik, Janessa Laskin, Cheryl Ho. (2015). Triage Nurse Navigator Implementation: Improvements in NSCLC Resource Utilization. 16th World Conference on Lung Cancer, ,  
Abstract  
Last Author  
Published
105. Joshua Giambattista, Nevin McVicar, Monty Martin, Cheryl Ho, Benjamin Maas, John Hay, Jonn Wu, Mira Keyes, Eric Berthelet. (2015). Magnitude and timing of GTV response to neoadjuvant chemotherapy and concurrent chemo-radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. CARO 2015, ,  
Abstract  
Co-Author  
Published
106. Georgia Geller, Brandon S. Sheffield, Susanna Zachara-Szczakowski, Katy Milne, Brad Nelson, Diana Ionescu, Cheryl Ho. (2015). Clinical Characteristics Associated with PDL1 Positive Status in Resected NSCLC. 16th World Conference on Lung Cancer, ,  
Abstract  
Last Author  
Published
107. BS Sheffield, Geller G, Pleasance E, Zachara-Szczakowski S, Milne K, Kalloger SE, Zhao E, Bidnur S, Jones M, Nelson BH, Yip S, Marra MA, Laskin J, Ho C, Ionescu DN. (2015). Predictive Biomarker Testing for Programmed Death 1 Inhibition in Non-Small Cell Lung Cancer. 16th World Conference on Lung Cancer, ,  
Abstract  
Co-Author  
Published
108. David Anderson, Alex DeCaluwe, Ted Toriumi, Cheryl Ho, Fred Hsu. (2015). EGFR mutation status and the metastatic behaviour of non-small cell lung cancer. CARO 2015, ,  
Poster  
Co-Author  
Published
109. David Anderson, Fred Hsu, Alex DeCaluwe, Ted Toriumi, Yvonne Zheng, Cheryl Ho. (2015). EGFR mutation testing in patients with metastatic non-small cell lung cancer – early pattern of practice in British Columbia. CARO 2015, ,  
Poster  
Last Author  
Published

110. Ren Yuan, Andrew Yamada, Britta Weber, Cheryl Ho. (2015). Early versus Late Brain Metastases in Wild Type and Mutation Positive EGFR Patients. 16th World Conference on Lung Cancer, ,  
Abstract  
Last Author  
Published